InnoCare announces approval of clinical trial of a novel ADC ICP-B794 in China

CAR-T Digest - August 2020

04 July 2025: InnoCare announces approval of clinical trial of a novel ADC ICP-B794 in China

InnoCare Pharma received IND approval from China’s NMPA to begin clinical trials for ICP-B794, a novel B7-H3 targeted antibody-drug conjugate (ADC) for treating various solid tumors
ICP-B794 consists of a humanized anti-B7-H3 monoclonal antibody linked to a potent in-house developed payload via a protease-cleavable linker, designed to maximize tumor targeting while minimizing off-target effects
InnoCare is leveraging its proprietary ADC platform and expanding its oncology pipeline with differentiated therapies like ICP-B794 and TRK inhibitor Zurletrectinib (ICP-723), aiming to advance precision medicine in solid tumors